Section
Fludarabine, cyclophosphamide, and low-dose TBI combined with post-transplant cyclophosphamide provide a safe and effective single platform for haploidentical and unrelated donor allo-SCT in older AML/MDS patients, showing favorable surviva
CD79B expression in diffuse large B-cell lymphoma (DLBCL) exhibits a distinct gradient aligned with cell-of-origin subtypes and germinal center B-cell differentiation stages, highlighting the biological basis for differential therapy respon
EBV-positive diffuse large B-cell lymphoma exhibits severe systemic antiviral T-cell impairments and a suppressive tumor microenvironment driven by LMP1, revealing novel immunobiological insights with therapeutic implications.
Shorter diagnosis-to-treatment intervals independently predict worse outcomes in follicular lymphoma treated with immunochemotherapy, highlighting a novel prognostic factor beyond existing risk indices.
Fecal calprotectin offers a non-invasive, dynamic biomarker to predict, diagnose, and monitor GI-GVHD post-allo-HSCT, correlating with endoscopic severity and treatment response, but requires integrated clinical interpretation due to limite
Dual inhibition of CDK2 and CDK4/6 demonstrates synergistic anti-leukemic effects in AML by suppressing the Rb/E2F axis, offering a promising therapeutic strategy to improve outcomes in this challenging hematologic malignancy.
The EURO-SKI Biomarker Study elucidates molecular signatures and immune interactions underlying treatment-free remission and relapse in chronic myeloid leukemia patients discontinuing tyrosine kinase inhibitors, highlighting immune communic
Severe allergic transfusion reactions in group O recipients receiving group B or AB plasma or platelets are linked to IgE antibodies against the α-Gal epitope, highlighting a novel immunological mechanism and potential risk stratification a
A Japanese registry study of 929 patients aged 70+ identified six predictors of worse survival after allo-HSCT and created a simple score that sharply stratified 2-year overall survival from 57.1% to 2.5%.
BRAF mutations occur in about 1% of AML and are usually non-V600 variants enriched in myelodysplasia-related disease. This cohort study found poor survival and suggested that current therapies, including venetoclax-based regimens, remain in
Complement deposition on platelets identifies a biologically distinct subset of adult ITP associated with higher platelet turnover and more first-line treatment refractoriness.
A large real-world study found GLP-1 receptor agonists were associated with better survival and lower locoregional recurrence than bariatric surgery in postmenopausal women with obesity and breast cancer.
Low fibrinogen alone did not prevent arterial thrombosis in humans or mice, but loss of the fibrinogen αC region reduced clot formation. The study suggests fibrinogen structure, not just level, influences arterial thrombotic risk.
A large EBMT registry study suggests that escalating fludarabine during lymphodepletion does not improve tisagenlecleucel outcomes in LBCL and may worsen survival, while axicabtagene ciloleucel retains superior efficacy at standard dosing b
Patients with primary cancer who had pre-diagnostic CHIP faced a higher risk of second cancers, especially blood cancers. The findings suggest CHIP may help identify survivors who need closer long-term monitoring.
A new Blood study links relapse after myeloma ASCT to CSF-1R+ immunosuppressive marrow macrophages and shows that CSF-1R inhibition synergizes with lenalidomide in preclinical models, providing a strong translational rationale for post-tran
Extended follow-up from ASTRUM-005 shows serplulimab plus chemotherapy improves long-term survival in untreated extensive-stage small cell lung cancer, with manageable safety and encouraging patient-reported outcomes.
A phase 1 study suggests non-gene-edited allogeneic CD19 CAR-T therapy can induce remissions in relapsed or refractory B-ALL without observed GVHD, though durability remains limited and larger trials are needed.
Immune checkpoint therapy has become a major advance in pediatric Hodgkin lymphoma and is now being actively tested across selected pediatric non-Hodgkin lymphomas with strong PD-L1 biology.
Mouse and human observational data suggest that the fibrinogen αC region is a key determinant of arterial thrombosis under hypofibrinogenemic conditions, likely through platelet GPVI-dependent mechanisms.
